30 closest matches · ranked by relevance
Neisseria Meningitidis
Primary: Estimate the Difference in Carriage Prevalence of Disease Associated Genogroups of N. Meningitidis (A, B, C, W, X, Y) Between School Leavers in 2018 (Year 12 in 2017)…
N. Meningitidis Carriage
Primary: Percentages of Subjects With Carriage of Virulent Sequence Types (ST) of Neisseria Meningitidis Group B, One Month After Completion of rMenB+OMV NZ Vaccination — 8; 7…
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Carriage of Streptococcus Pneumoniae in Nasopharynx — 12.6 Percentage of Participants
Streptococcus Pneumoniae Infections
Primary: Percentage of Participants With Nasopharyngeal Carriage of Streptococcus Pneumoniae — 12.5; 7.2; 16.6; 9.3 percentage of participants
Pneumococcal Disease
Primary: Prevalence of Streptococcus Pneumoniae in Nasopharynx — 76; 43; 86; 46 Participants
Preference, Patient
Primary: Prevalence — 16 Participants
Meningococcal Infections · Meningitis
Primary: Percentage of Participants With Serum Bactericidal Antibody Titers for Meningococcal Serogroups A, C, Y, and W-135 at ≥ 8 and ≥ 128 at Enrollment — 53; 34; 20; 50…
Nasopharyngeal Carriage of S. Pneumoniae
Primary: Nasopharngeal Colonization With PCV13 S. Pneumoniae — 20; 31; 166; 137 Participants — p=<0.05
Meningococcal Meningitis
Primary: Percentages of Subjects With Human Complement Serum Bactericidal Activity (hSBA) Titers≥ 1:8, After One Dose of Either MenACWY-CRM Conjugate or Licensed Comparator…
Infections, Meningococcal
Primary: Vaccine Response to Meningococcal Antigens for Serum Bactericidal Assay Using Rabbit Complement (rSBA) — 82.7; 69.7; 94.4; 90.3 Percentage of subjects
Meningitis · Meningococcal Infection
Primary: Participants With Serum Bactericidal Activity of ≥ 1:8 for Each Menactra® Vaccine Serogroups Pre-vaccination and 28 Days Post-booster or Post-primary Dose Vaccination…
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Percentage of Participants With Meningococcal Antibody Titers ≥ 1:4 Before, 28 Days After, and Approximately Four Years Following Menactra Vaccine Booster Vaccination…
Infections, Meningococcal
Primary: Number of Subjects With Serum Bactericidal Assay (Using Human Complement) (hSBA) Titers Equal to or Above the Cut-off Values — 102; 35; 15; 319 Subjects
Meningitis, Meningococcal
Primary: Severe Solicited Adverse Event — 0; 0; 0; 0 participants
Meningitis
Primary: Number of Participants With Seroprotection for Meningitis Serogroups A, C, W and Y — 373; 191; 366; 180 Participants
Meningitis · Meningococcal Infection
Primary: Percentage of Participants With Serum Bactericidal Activity of ≥ 1:8 for the Menactra® Meningococcal Serogroups Pre-vaccination, and at 7 Days or 14 Days Post-booster or…
Meningococcal Disease
Primary: Summary of Memory B Cells Per 2 x 105 LOC by Serogroup A, C, W-135 and Y — 2.10; 1.80; 1.72; 2.57 B cells per 2x100000 lymphocytes — p=0.69
Meningococcal Disease · Meningococcal Meningitis
Primary: Percentage of Participants With Serum Bactericidal Activity >=8 at 5 Years After Primary Vaccination — 30; 44; 11; 76 Percentage of participants
Neisseria Gonorrhoeae Infection
Primary: Change in Anti-N. Gonorrhoeae Outer-membrane Vesicle Specific Immunoglobulin G (IgG) Concentrations After Immunization — 61.57; 206.2 titers
Meningococcal ACWY Disease
Primary: Percentage of Participants With Booster Response in Terms of Serum Bactericidal Assay Using Rabbit Complement (rSBA) Titer Levels at 1 Month After Booster Vaccination…
Meningococcal Disease
Primary: Percentage of Subjects With Persisting Serum Bactericidal Antibody Titers ≥1:8, Upto 13-33 Months After Primary Vaccination With Either MenACWY-CRM or MenC Vaccine — 13…
Prevention of the Meningococcal Disease
Primary: Geometric Mean Human Serum Bactericidal Activity Titers Against N Meningitidis Serogroup B Strains Following A Two-dose Vaccination Schedule — 1.18; 53; 2.27; 143 Titers
Meningococcal Disease · Infections, Meningococcal
Primary: Percentages of Subjects With hSBA ≥ Lower Limit Quantitation (LLQ) Against N. Meningitidis Serogroups A, C, W and Y and Serogroup B Test Strains.
Meningococcal Meningitis
Primary: Percentages of Subjects With Human Serum Bactericidal Assay (hSBA) Titers ≥ 1:8 Directed Against N. Meningitidis Serogroups A, C, W-135, and Y — 10; 35; 2; 34…
Meningococcal Disease
Primary: Geometric Mean Titer of the Meningococcal B Vaccine Against the Different Strains at One Month After First, Second and Third Vaccination. — 2.5; 2.3; 1.8; 33 titer
Neisseria Meningitidis · Meningococcal Infections
Primary: Geometric Mean Titers (GMTs) of Vaccine Serogroups Determined by Serum Bactericidal Activity Using Baby Rabbit Complement (SBA-BR) Pre- and Post-Menactra® Vaccination…
Gonorrhoea
Primary: Rectal Mucosal IgG Concentrations (Geometric Mean Titers [GMT]) Against N. Gonorrhoeae Outer Membrane Vesicle (OMV) Antigen Ng1291 — 0.07; 0.072; 0.089; 0.097 titer
Meningococcal Disease · Meningococcal Meningitis
Primary: Number of Subjects Reporting Unsolicited Adverse Events, Following Vaccination With Two Injections of rMenB+OMV NZ Vaccine Between Day 1 Through Day 91. — 2; 0; 0; 0…
Meningitis · Meningococcal Meningitis · Meningococcal Infections
Primary: Number of Participants Reporting Solicited Injection Site or Systemic Reactions Following Vaccination With Either Menomune or Menactra Vaccine — 8; 33; 0; 1 Participants
Meningococcal Immunisation · Healthy Volunteers
Primary: Percentage of Participants With Antibody Titers >=1:8 Against Meningococcal Serogroups A, C, W, and Y Measured by hSBA Following Vaccination With MenACYW Conjugate…